FEATURES OF THE IMPACT OF NOVEL GLUCOSE-LOWERING DRUG CLASSES ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Type 2 diabetes mellitus (T2DM) is associated with high cardiovascular risk. This study evaluated the effects of novel glucose-lowering agents on cardiovascular outcomes. A total of 100 patients were divided into standard therapy and treatment including SGLT2 inhibitors and GLP-1 receptor agonists. Patients receiving novel therapies showed improved glycemic control, reduced inflammation, enhanced endothelial function, and a lower incidence of major adverse cardiovascular events (MACE). SGLT2 inhibitors were more effective in reducing heart failure risk, while GLP-1 receptor agonists better prevented atherosclerotic events. These findings support their use in cardiovascular risk reduction in T2DM.